Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...

Global drugmaker Novartis will lay off 427 employees in East Hanover this spring and summer, after it let go of 235 at the Morris County site last year, filings with the New Jersey Department of Labor ...

Novartis Pharmaceuticals is removing hundreds of New Jersey employees from its company. The global drugmaker will lay off 427 ...

Swiss drugmaker Novartis is ending its use of diverse panels for all of its hiring in the United States, the company told ...

Novartis was announced as an official partner of this year’s Eurovision competition last fall, after the song entry from ...

Swiss pharma major Novartis (NOVN: VX) is set to lay off 427 employees at its East Hanover, New Jersey, site as part of a ...

To Novartis, fresh late-stage data support the idea that its intrathecal drug, which has the same active ingredient as ...

Novartis Pharma Maroc has appointed Yahya Abdallah as country president for its Morocco, Tunisia, and Algeria (MTA) regional ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based ...

The US Food and Drug Administration (FDA) has approved Swiss pharma giant Novartis’ (NOVN: VX) oral Fabhalta (iptacopan) for ...